MedElevator
Войти в исследования Open forum infectious diseases · 2026
Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gouraud Camille, Putot Alain, Fraisse Thibaut, Bermejo Messaline, Viala Benjamin, Golstein Charlotte, Lemarie Nadège, Roubaud Baudron Claire, Caraux-Paz Pauline
Аннотация
BACKGROUND: Guidelines recommend fluoroquinolones or cotrimoxazole for urinary tract infections in men (UTIm), but safety data in frail older patients remain limited. The aim of this study was to compare the tolerability of these antibiotics in UTIm patients over age 75 years.
METHODS: This multicenter retrospective study included patients age ≥75 years who were hospitalized for UTIm in 8 hospitals and treated with oral fluoroquinolone or cotrimoxazole. Adverse events (AEs) during hospitalization were compared.
RESULTS: Among 228 patients (median age, 85 years), 131 (57.4%) received fluoroquinolones and 97 (42.6%) cotrimoxazole. Baseline characteristics were similar. AEs occurred in 29.7% of fluoroquinolone-treated patients vs 48.5% treated with cotrimoxazole (P = .006), leading to treatment discontinuation in 2.3% vs 11.3% (P = .009). Acute kidney injury was observed in 7.2% vs 29.4% (P < .001), metabolic disorders in 7.6% vs 18.6% (P = .023). Other AEs and mortality did not differ significantly. Cotrimoxazole was associated with a doubled risk of AEs (adjusted odds ratio, 2.10; 95% CI, 1.18-3.74; P = .01).
CONCLUSIONS: These results suggest a better safety profile of fluoroquinolones than cotrimoxazole in the treatment of UTI in older men. These results need to be confirmed in a prospective design.
METHODS: This multicenter retrospective study included patients age ≥75 years who were hospitalized for UTIm in 8 hospitals and treated with oral fluoroquinolone or cotrimoxazole. Adverse events (AEs) during hospitalization were compared.
RESULTS: Among 228 patients (median age, 85 years), 131 (57.4%) received fluoroquinolones and 97 (42.6%) cotrimoxazole. Baseline characteristics were similar. AEs occurred in 29.7% of fluoroquinolone-treated patients vs 48.5% treated with cotrimoxazole (P = .006), leading to treatment discontinuation in 2.3% vs 11.3% (P = .009). Acute kidney injury was observed in 7.2% vs 29.4% (P < .001), metabolic disorders in 7.6% vs 18.6% (P = .023). Other AEs and mortality did not differ significantly. Cotrimoxazole was associated with a doubled risk of AEs (adjusted odds ratio, 2.10; 95% CI, 1.18-3.74; P = .01).
CONCLUSIONS: These results suggest a better safety profile of fluoroquinolones than cotrimoxazole in the treatment of UTI in older men. These results need to be confirmed in a prospective design.